It’s not uncommon for companies who launch commercial drug products in the pre-filled syringe format to do so after initially using other product formats such as vials for the development and clinical trial phases. Switch-overs need careful and strategic consideration because doing so requires investment in the new format but also offers critical patient benefits and improved stakeholder outcomes.
During this webinar, you will learn more about benefits and risks of changing primary components during product development and how a design of experiments approach can be used to address issues and risks:
- Reducing risk of cross contamination
- Minimizing risk of injuries with physicians as minor manipulation
- Ensuring dose accuracy
- Reducing costs especially for expensive biologics